Related Experiment Video
Updated: Jul 14, 2026
11:04
The Citrobacter rodentium Mouse Model: Studying Pathogen and Host Contributions to Infectious Colitis
Published on: February 19, 2013
A new role for cathelicidin in ulcerative colitis in mice
Emily K K Tai1, William K K Wu, Helen P S Wong
1Department of Pharmacology, The University of Hong Kong, Hong Kong, China.
Experimental Biology and Medicine (Maywood, N.J.)
|May 29, 2007
Summary
Cathelicidin, an antimicrobial peptide, shows promise for treating inflammatory bowel diseases (IBDs). This study found that mouse cathelicidin-related antimicrobial peptide (mCRAMP) reduced colitis symptoms and fecal microbes in mice.
Area of Science:
- Immunology
- Gastroenterology
- Peptide Therapeutics
Background:
- Cathelicidin is a key component of the innate immune system, influencing microbial balance, wound repair, and inflammation.
- The role of cathelicidin in inflammatory bowel diseases (IBDs) remains largely unexplored.
Purpose of the Study:
- To investigate the potential of cathelicidin to modulate IBD progression.
- To elucidate the mechanism by which cathelicidin exerts its effects in experimental colitis.
Main Methods:
- A synthetic cathelicidin, mCRAMP, was administered to mice with dextran sulfate sodium (DSS)-induced colitis, both concurrently and post-induction.
- Evaluated parameters included body weight, fecal microflora, clinical signs, colonic histology, mucin gene expression (MUC1-4), and apoptosis.
Main Results:
- Intrarectal mCRAMP administration ameliorated DSS-induced colitis, significantly reducing fecal microflora and preventing colitis development.
- mCRAMP reversed the reduction in colonic mucus thickness by upregulating mucin gene expression and suppressed DSS-induced apoptosis.
Conclusions:
- Cathelicidin, specifically mCRAMP, demonstrates a therapeutic potential for IBD.
- Intrarectal administration of cathelicidin may represent a novel therapeutic strategy for managing inflammatory bowel diseases.
